Hikma Pharmaceuticals
Hikma focuses on a wide range of generic, branded generic and in licensed pharmaceutical products.
Launch date
Employees
Market cap
AUD8.7b
Enterprise valuation
AUD10.2b (Public information from Sep 2024)
Share price
£19.60072 HIK.L
Company register number 05557934
London England (HQ & founding location)
Corporate Venture Fund: Hikma Ventures
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.2b | 2.3b | 2.6b | 2.5b | 2.9b | 2.3b | 2.4b |
| % growth | (19 %) | 6 % | 9 % | (1 %) | 14 % | (19 %) | 3 % |
| EBITDA | 659m | 652m | 735m | 700m | 871m | - | - |
| % EBITDA margin | 30 % | 28 % | 29 % | 28 % | 30 % | - | - |
| Profit | 486m | 431m | 421m | 188m | 190m | - | - |
| % profit margin | 22 % | 18 % | 16 % | 7 % | 7 % | - | - |
| R&D budget | 150m | 137m | 143m | 144m | 149m | - | - |
| R&D % of revenue | 7 % | 6 % | 6 % | 6 % | 5 % | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Hikma Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
By Country
By Industry
By Round
Investments by Hikma Pharmaceuticals
Edit
ACQUISITION by Hikma Pharmaceuticals Sep 2021
ACQUISITION by Hikma Pharmaceuticals Dec 2007
ACQUISITION by Hikma Pharmaceuticals May 2007
